Pluri Inc.
PLURPluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is Pluri Inc.'s next FDA catalyst?→
Pluri Inc.'s (PLUR) next tracked catalyst is a Earnings expected November 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PLUR biotech catalysts?→
Add PLUR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pluri Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.